Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218288 | 1.00 | CHRM5 (0.58) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL30340999 | 1.00 | CHRM5 (0.58) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL10949210 | 0.97 | CHRM5 (0.54) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL11850078 | 0.92 | CYP1A2 (0.48) | CHRM5ADRA2CCYP1A2SIGMAR1CHRM3 | |
| SCHEMBL10153844 | 0.92 | CYP1A2 (0.54) | CHRM5ADRA2CCYP1A2HRH3 | |
| SCHEMBL8587237 | 0.90 | CYP1A2 (0.50) | CHRM5ADRA2CCYP1A2HRH3 | |
| SCHEMBL24146230 | 0.86 | CYP1A2 (0.44) | CHRM5ADRA2CCYP1A2SIGMAR1CHRM3 | |
| SCHEMBL30115021 | 0.86 | HRH3 (0.54) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL30115019 | 0.86 | HRH3 (0.54) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL7166922 | 0.85 | CYP1A2 (0.44) | CHRM5ADRA2CCYP1A2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885CYP1A2 2997/4885 |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885CYP1A2 2997/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885CYP1A2 2997/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885CYP1A2 2997/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CHRM5 4367/4885ADRA2C 4410/4885CYP1A2 4777/4885 |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | CHRM5 4613/4885ADRA2C 2466/4885CYP1A2 2355/4885 |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | CHRM5 473/4885ADRA2C 350/4885CYP1A2 659/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885CYP1A2 2997/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885CYP1A2 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.